Viron Therapeutics is a clinical stage biopharmaceutical company pioneering the development of viral proteins to treat and prevent human inflammatory disorders.  Viral proteins represent a revolutionary new class of drugs.  By harnessing the evolutionary power of viruses and other pathogens to evade the human body's protective inflammatory response, Viron is able to identify and develop powerful protein therapeutics that have distinct advantages in potency and efficacy over conventional drug therapy.  Viron is the first company to successfully advance a viral protein drug into human testing.  Viron recently reported positive Phase IIa data evaluating its lead compound, VT-111, for the treatment of vascular inflammation in patients with Acute Coronary Syndromes.  The results demonstrated that VT-111 significantly reduces key cardiac enzymes after stent placement.  Viron's pipeline of additional compounds in preclinical development, combined with a robust discovery program, strongly positions the Company to be a leader in the discovery and commercialization of bio-therapeutics to treat inflammatory-based diseases.